Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice

• Published in: Vaccine Vol. 42; no. 25; p. 126213
• Main Authors: Valdes, Iris, Suzarte, Edith, Lazo, Laura, Cobas, Karem, Cabrales, Ania, Pérez, Yusleidi, Garateix, Rocío, Silva, José A., Aguilar, Julio C., Guzman, Carlos A., Guillén, Gerardo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 14.11.2024; Elsevier Limited
• Subjects: Adjuvants; Adjuvants, Immunologic - administration & dosage; Adjuvants, Vaccine; Aluminum; Aluminum hydroxide; Animals; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; Antigens; c-di-AMP; Capsid; Capsid Proteins - immunology; Cell-mediated immunity; Chromatography; Combined vaccines; Dengue fever; Domain III; Female; Guillain-Barre syndrome; Immune response; Immune response (cell-mediated); Immune system; Immunity; Immunity (Disease); Immunity, Cellular; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunology; Immunomodulation; Immunomodulators; Infections; Laboratory animals; Lymphocytes T; Mice; Mice, Inbred BALB C; mRNA vaccines; Neutralizing antibodies; Nucleotides; Oligodeoxyribonucleotides - administration & dosage; Oligodeoxyribonucleotides - immunology; Population studies; Proteins; Public health; Recombinant protein; Signal transduction; Vaccine; Vaccine development; Vaccines; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - immunology; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology; Vector-borne diseases; Viral Envelope Proteins - immunology; Viral infections; Viral Vaccines - administration & dosage; Viral Vaccines - immunology; Viruses; West Nile virus; Zika virus; Zika Virus - immunology; Zika Virus Infection - immunology; Zika Virus Infection - prevention & control; γ-Interferon; Cell-mediated immunity; Neutralizing antibodies; Immunomodulation; Domain III; c-di-AMP; Zika virus; Vaccine; Recombinant protein; Capsid
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2024.126213

Zika virus (ZIKV) infection remains a global public health problem. After the “Public Health Emergencies of International Concern” declared in February 2016, the incidence of new infections by this pathogen has been decreasing in many areas. However, there is still a likely risk that ZIKV will spread to more countries. To date, there is no vaccine or antiviral drug available to prevent or treat Zika virus infection. In the Zika vaccine development, those based on protein subunits are attractive as a non-replicable platform due to their potentially enhanced safety profile to be used in all populations. However, these vaccines frequently require multiple doses and adjuvants to achieve protective immunity. In this study we show the immunological evaluation of new formulations of the recombinant protein ZEC, which combines regions of domain III of the envelope and the capsid from ZIKV. Two nucleotide-based adjuvants were used to enhance the immunity elicited by the vaccine candidate ZEC. ODN 39M or c-di-AMP was incorporated as immunomodulator into the formulations combined with aluminum hydroxide. Following immunizations in immunocompetent BALB/c mice, the formulations stimulated high IgG antibodies. Although the IgG subtypes suggested a predominantly Th1-biased immune response by the formulation including the ODN 39M, cellular immune responses measured by IFNγ secretion from spleen cells after in vitro stimulations were induced by both immunomodulators. These results demonstrate the capacity of both immunomodulators to enhance the immunogenicity of the recombinant subunit ZEC as a vaccine candidate against ZIKV.